Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Authors: Abhishek Maiti, Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi, Guillermo Garcia‐Manero, Gautam Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas J. Short, Yesid Alvarado, Tapan M. Kadia, Koichi Takahashi, Musa Yılmaz, Nitin Jain, Steven M. Kornblau, Guillermo Montalban‐Bravo, Koji Sasaki, Michael Andreeff, Prithiviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias Jabbour, Lucia Masárová, Philip A. Thompson, Sa Wang, Sergej Konoplev, Sherry Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Konopleva - Haematologica 2020 cited by 173

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. ] However, little is known about outcomes of patients after failure of front-line venetoclax-based regimens. We found that patients failing front-line VEN+HMA have high-risk biology, dismal overall survival (OS) despite salvage therapy, and new putative mechanisms of resistance. This knowledge may help guide physicians' expectations, inform discussion with patients, and design clinical trials in patients after venetoclax failure.